Case Report| Volume 274, P30-32, June 2023

Download started.


Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment


      Secondary hematologic malignancies, such as B-cell acute lymphoblastic leukemia/lymphoma (B-ALL), have been reported following multiple myeloma. Tyrosine kinase inhibitors have improved clinical outcomes of patients with Philadelphia-positive (Ph+) B-ALL. Therefore, recognition of the Ph chromosome in B-ALL patients is important for both prognosis and therapies. We present a case of a secondary Ph+ B-ALL following multiple myeloma that highlights a BCR::ABL1 fusion by a gene fusion assay to reveal a cryptic Ph chromosome, which may otherwise be missed by conventional cytogenetics and typical interphase fluorescence in situ hybridization.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mailankody S.
        • Pfeiffer RM
        • Kristinsson SY
        • et al.
        Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).
        Blood. 2011; 118: 4086-4092
        • Aldoss I.
        • Capelletti M
        • Park J
        • et al.
        Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.
        Leukemia. 2019; 33: 266-270
        • Shtivelman E.
        • Lifshitz B
        • Gale RP
        • et al.
        Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.
        Nature. 1985; 315: 550-554
        • El Fakih R.
        • Jabbour E
        • Ravandi F
        • et al.
        Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
        Am J Hematol. 2018; 93: 286-295
        • Haley L.
        • Parimi V
        • Jiang L
        • et al.
        Diagnostic utility of gene fusion panel to detect gene fusions in fresh and formalin-fixed, paraffin-embedded cancer specimens.
        J Mol Diagn. 2021; 23: 1343-1358
        • Jiang L
        • Pallavajjala A
        • Huang J
        • et al.
        Clinical utility of targeted next-generation sequencing assay to detect copy number variants associated with myelodysplastic syndrome in myeloid malignancies.
        J Mol Diagn. 2021; 23: 467-483
        • Jones J.R.
        • Cairns DA
        • Gregory WM
        • et al.
        Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
        Blood Cancer J. 2016; 6: e506
        • Kotchetkov R.
        • Masih-Khan E
        • Chu C
        • et al.
        Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
        Cancer Med. 2017; 6: 3-11
        • Aldoss I.
        • Dagis A
        • Palmer J
        • et al.
        Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome.
        Bone Marrow Transplant. 2015; 50: 746-748
        • Tang G.
        • Zuo Z
        • Thomas DA
        • et al.
        Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?.
        Haematologica. 2012; 97: 919-925
        • Bao F.
        • Munker R
        • Lowery C
        • et al.
        Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
        Mol Diagn Ther. 2007; 11: 239-245